Bruker Co. (NASDAQ:BRKR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $81.40.

A number of brokerages have commented on BRKR. The Goldman Sachs Group decreased their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. StockNews.com lowered shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Stifel Nicolaus reduced their target price on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a research note on Monday, May 20th. Jefferies Financial Group assumed coverage on shares of Bruker in a research note on Monday, June 3rd. They issued a “buy” rating and a $85.00 target price for the company. Finally, TD Cowen reduced their target price on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Wednesday, August 7th.

Bruker Stock Performance

NASDAQ:BRKR opened at $67.19 on Friday. The company has a fifty day moving average of $63.87 and a 200-day moving average of $74.74. The firm has a market capitalization of $9.77 billion, a P/E ratio of 24.43, a P/E/G ratio of 2.39 and a beta of 1.20. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting the consensus estimate of $0.52. The company had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. Bruker’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.50 EPS. As a group, sell-side analysts anticipate that Bruker will post 2.66 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Monday, September 2nd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, August 30th. Bruker’s dividend payout ratio (DPR) is currently 7.27%.

Hedge Funds Weigh In On Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new position in shares of Bruker in the 1st quarter worth about $27,000. Lindbrook Capital LLC lifted its holdings in Bruker by 68.2% during the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 146 shares during the last quarter. Covestor Ltd lifted its holdings in Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 210 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Bruker during the fourth quarter valued at about $30,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.